HKEX reported a 15% gain in net income and claims a robust IPO pipeline (100+ active applications), specifically in AI and Biotech. Exchanges are volume plays. A recovering property market and a backlog of IPOs (driven by domestic Chinese tech firms needing capital) suggest a recovery in listing fees and trading volumes. LONG. Continued geopolitical tensions or a lack of liquidity from foreign investors.